Mundipharma International Limited

mundipharma.com

Mundipharma International and the Mundipharma independent associated companies are passionately committed to improving the health and quality of life of people everywhere. Over the past 50 years the network of independent associated companies has become a leader in pain management, and through a shared spirit of innovation is building a growing presence in the oncology, rheumatoid arthritis and respiratory markets.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Practice Management

INFANT BACTERIAL THERAPEUTICS TODAY ANNOUNCES NEW PATENT PROTECTION APPROVALS IN BRAZIL AND IN HONG KONG

Infant Bacterial Therapeutics | December 28, 2021

news image

Infant Bacterial Therapeutics AB announces that the Patent Offices of Brazil and Hong Kong have approved a patent of Lactobacillus reuteri covering IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of necrotizing colitis and improvement of feeding tolerance in preterm infants. The patent covers a novel way to activate the bacteria. Corresponding patent applications are currently pending across several important future markets. This p...

Read More

KIMERA® LABS FILES FIRST FDA INVESTIGATIONAL NEW DRUG (IND) APPLICATION USING XOGLO® FOR TREATMENT OF ARDS SECONDARY TO COVID-19

Prnewswire | August 18, 2020

news image

Kimera® Labs Inc, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes. Founded in 2012, Kimera® generated the first publicly available isolated exosome product and has treated over 35,000 thousand patients for a variety of investigatio...

Read More

VIEWS AND ANALYSIS, PHARMA TECH

NOVAVAX ANNOUNCES PRICING OF $150 MILLION OFFERING OF CONVERTIBLE SENIOR NOTES

Novavax, Inc. | December 16, 2022

news image

Novavax, Inc. a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of $150 million aggregate principal amount of its 5.00% convertible senior notes due 2027. The notes are being offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In connection with the offering of the notes, No...

Read More

PHARMA TECH

AION LABS WELCOMES AMITI AS STRATEGIC PARTNER TO ACCELERATE ISRAEL'S POSITION AS A LEADING HUB FOR TRANSFORMATIVE AI-POWERED DRUG DISCOVERY INNOVATION

PR Newswire | January 09, 2024

news image

AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today a new strategic partnership with Amiti Ventures, one of the leading early-stage venture capital firms in Israel. The partnership further strengthens the alliance of global leaders in pharma, biotech, and technology investment, expanding its offering as a venture studio and partner for new startups. "With a pr...

Read More
news image

Practice Management

INFANT BACTERIAL THERAPEUTICS TODAY ANNOUNCES NEW PATENT PROTECTION APPROVALS IN BRAZIL AND IN HONG KONG

Infant Bacterial Therapeutics | December 28, 2021

Infant Bacterial Therapeutics AB announces that the Patent Offices of Brazil and Hong Kong have approved a patent of Lactobacillus reuteri covering IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of necrotizing colitis and improvement of feeding tolerance in preterm infants. The patent covers a novel way to activate the bacteria. Corresponding patent applications are currently pending across several important future markets. This p...

Read More
news image

KIMERA® LABS FILES FIRST FDA INVESTIGATIONAL NEW DRUG (IND) APPLICATION USING XOGLO® FOR TREATMENT OF ARDS SECONDARY TO COVID-19

Prnewswire | August 18, 2020

Kimera® Labs Inc, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes. Founded in 2012, Kimera® generated the first publicly available isolated exosome product and has treated over 35,000 thousand patients for a variety of investigatio...

Read More
news image

VIEWS AND ANALYSIS, PHARMA TECH

NOVAVAX ANNOUNCES PRICING OF $150 MILLION OFFERING OF CONVERTIBLE SENIOR NOTES

Novavax, Inc. | December 16, 2022

Novavax, Inc. a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of $150 million aggregate principal amount of its 5.00% convertible senior notes due 2027. The notes are being offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In connection with the offering of the notes, No...

Read More
news image

PHARMA TECH

AION LABS WELCOMES AMITI AS STRATEGIC PARTNER TO ACCELERATE ISRAEL'S POSITION AS A LEADING HUB FOR TRANSFORMATIVE AI-POWERED DRUG DISCOVERY INNOVATION

PR Newswire | January 09, 2024

AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today a new strategic partnership with Amiti Ventures, one of the leading early-stage venture capital firms in Israel. The partnership further strengthens the alliance of global leaders in pharma, biotech, and technology investment, expanding its offering as a venture studio and partner for new startups. "With a pr...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us